Puma announces acceptance of alisertib + pembrolizumab poster at AACR-NCI-EORTC conference

PUMA BIOTECHNOLOGY, INC.

Investigator-sponsored Phase I/II trial of alisertib plus pembrolizumab accepted for poster presentation.
Trial targets Rb-deficient head and neck squamous cell carcinoma (HNSCC).
Poster presentation at late-breaking session C on Oct 14, 2023, 12:30-4:00 pm ET, as LB_C12.
Conference: 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston.
No clinical data results announced; this is a trial update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.